+ Watch SOMX.DL
on My Watchlist
A pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology.
Despite the 15% upward heave today, I think Somaxon is the next Labopharm, a small pharma that had to sell itself for a pittance recently because no one bought the drugs that they slaved for years to develop. Similarly, Silenor has proven itself to have weak commercial potential, with revenues consistently failing to approach the cost of sales.An uptick in revenues from 2.3M to 6.2M last quarter may have inspired some optimism, but I believe the increase was exclusively due to a change in revenue recognition methodology to reflect sales to distributors rather than filling of prescriptions. If I'm correct, quarterly revenues to be reported in early November may crush the share price and send the stock on a downward spiral from which it won't recover.The company has made some noise about pursuing OTC approval for Silenor, but Feuerstein feels that they are years away from any such achievement. Meanwhile the company is burning about 15M a quarter and had 33M in cash at the end of June. Within a year they will have taken full advantage of a 15M debt facility with Oxford and a 30M ATM agreement with Citadel. This may keep operations afloat, but the street doesn't look favorably on small pharmas floating in a sea of dilution and debt. On November 3, this toilet might get flushed.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions